Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

著者: René S. Kahn, Inge Winter van Rossum, Stefan Leucht, Philip McGuire, Shôn Lewis, Shon W Lewis, Celso Arango, Paola Dazzan, Richard Drake, Stephan Heres, Covadonga M. Díaz‐Caneja, Covadonga M Díaz-Caneja, Mark Weiser, Silvana Galderisi, Birte Glenthøj, Marinus J.C. Eijkemans, W. Wolfgang Fleischhacker, Shitij Kapur, Iris E. Sommer, René S. Kahn, Iris E. Sommer, Inge Winter-van Rossum, Metten Somers, Paula C Ywema, S. Kapur, Philip McGuire, Shitisj Kapur, Andreas Meyer‐Lindenberg, Shôn Lewis, Stefan Leucht, Celso Arango, Wolfgang Fleischhacker, Anne Lotte Meijering, Jocelyn Petter, Resy van de Brug, Joost Schotsman, Jildou Zwerver, Jos Peuskens, Jildou Zwerver, E Thys, Lucho G Hranov, Valentin Hranov, Jan Libiger, Richard M. Köhler, Pavel Mohr, Birte Glenthøj, Brian V. Broberg, Signe Wegmann Düring, Lone Baandrup, Stéphane Jamain, Lone Baandrup, Stephane Jamain, Ina Giegling, Dan Rujescu, M Heim, Michael Davidson, Mor Bar Heim, Paola Bucci, Armida Mucci, Janusz Rybakowski, Agnieszka Remlinger-Molenda, Ilan Gonen, Paull Radu, Marina Díaz‐Marsá, Alberto González Rodríguez, Tomás Palomo, Roberto Rodríguez–Jiménez, Tomas Palomo, Miquel Bernardo, Julio Bobes, Christina Vilares Oliveira, Gregor Berger, Claudia Wildt, Paola Dazzan, Roccio Perez-Iglesias, Richard Drake, Sarah Gregory, Danielle Wilson, Covadonga M. Díaz‐Caneja, Marinus J.C. Eijkemans, Covadonga M. Díaz‐Caneja, Marinus J.C. Eijkemans - The Lancet 2018 被引用: 197